Moritz Hunkeler

Jul 28, 2024 | nature.com | Moritz Hunkeler |Mingxing Teng |Justine C. Rutter |Anna M Schmoker |Rebecca Metivier |Woong Sub Byun | +9 more

AbstractMolecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite discovery. Here we unveil a trans-labeling covalent molecular glue mechanism, termed ‘template-assisted covalent modification’.

Apr 29, 2024 | nature.com | Raymond Carter |Baranda S. Hansen |Katherine A. Donovan |Moritz Hunkeler |Wojciech Rosikiewicz |Meghan G. McReynolds | +8 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07250-1 Published online 27 March 2024In the version of the article initially published, the far-right labels in Fig. 4h (now reading “Viable cells” and “Lethal in SMARCB1-deficient RT cells”) were swapped and have now been corrected in the HTML and PDF versions of the article. About this articleRadko-Juettner, S., Yue, H., Myers, J.A. et al. Author Correction: Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.

Mar 27, 2024 | nature.com | Raymond Carter |Baranda S. Hansen |Katherine A. Donovan |Moritz Hunkeler |Wojciech Rosikiewicz |Nada Mageed | +8 more

AbstractWhereas oncogenes can potentially be inhibited with small molecules, the loss of tumour suppressors is more common and is problematic because the tumour-suppressor proteins are no longer present to be targeted. Notable examples include SMARCB1-mutant cancers, which are highly lethal malignancies driven by the inactivation of a subunit of SWI/SNF (also known as BAF) chromatin-remodelling complexes.